This article delves into the intricate challenges that the radiopharmaceutical sector faces and emphasizes the pivotal role of innovative automation solutions in overcoming obstacles.

EVEON and CONICIO, a design and engineering agency, have signed a partnership agreement. The two companies aim to strengthen their collaborations, as the consideration of human factors (ergonomics, usability) in the development of innovative medical devices is crucial for their use by patients and healthcare professionals.

The pharmaceutical industry has undergone a remarkable shift in the delivery route for pharmaceutical products, with injectable drugs taking center stage. According to the U.S. Food and Drug Administration (FDA), injectables now account for 40% of newly approved drugs, primarily administered via subcutaneous and intramuscular routes. This paradigm shift necessitates new strategies that prioritize patient-centric approaches to enhance treatment adherence.

EVEON has developed an additional version of Intuity® Mix, its platform dedicated to the automatic preparation of innovative therapeutics

Read the latest article published in OnDrugDelivery about the challenges faced by the injectable drug delivery industry. And how EVEON’s solution – the Intuity® Ject MX platform overcomes these challenges, offering a fully automatic autoinjector that enables drug mixing, dosing and injection in the same handheld device.

EVEON is attending in various events this Spring 2023. Save the dates and come to meet us and discuss about your needs and how adaptive optics can improve your projects.

Cell and gene therapy delivery is an emergent and transformative industry. 

EVEON and Sensorion collaborating to develop an injection system for the delivery of gene therapy treatments into the inner ear

EVEON exhibited at Pharmapack - booth F68 and at Innovation Gallery, on February 1-2, 2023 in Paris (France). 

Read the latest article published in OnDrugDelivery about the current challenges faced by the topical spray-based delivery of therapeutics. And how our Ad-Mist™ spray nozzle overcomes these challenges to harness the potential of this delivery route.